{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:05:08Z","timestamp":1789535108460,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10549-026-08077-2","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:38:17Z","timestamp":1789533497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrin \u03b12 (CD49b) blockade remodels the tumor immune microenvironment and enhances anti-PD-L1 therapy in 4T1 breast cancer model"],"prefix":"10.1007","volume":"219","author":[{"given":"Ibrahim Ragab","family":"Eissa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth K.","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"1","key":"8077_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1741-7015-6-11","volume":"6","author":"PP Provenzano","year":"2008","unstructured":"Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, White JG, Keely PJ (2008) Collagen density promotes mammary tumor initiation and progression. BMC Med 6(1):11. https:\/\/doi.org\/10.1186\/1741-7015-6-11","journal-title":"BMC Med"},{"issue":"5","key":"8077_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","volume":"139","author":"KR Levental","year":"2009","unstructured":"Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SFT, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139(5):891\u2013906. https:\/\/doi.org\/10.1016\/j.cell.2009.10.027","journal-title":"Cell"},{"issue":"6230","key":"8077_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348(6230):74\u201380. https:\/\/doi.org\/10.1126\/science.aaa6204","journal-title":"Science"},{"issue":"1","key":"8077_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12672-025-04182-8","volume":"17","author":"D Wu","year":"2025","unstructured":"Wu D, Liu L, Jiang Y, Qian Z, You Y, Ning X, Zhang F, Wang Y, Zhang Y (2025) Collagen dynamics in the breast cancer tumor microenvironment and therapeutic perspectives. Discov Onc 17(1):9. https:\/\/doi.org\/10.1007\/s12672-025-04182-8","journal-title":"Discov Onc"},{"issue":"10","key":"8077_CR5","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1039\/c5ib00040h","volume":"7","author":"I Acerbi","year":"2015","unstructured":"Acerbi I, Cassereau L, Dean I, Shi Q, Au A, Park C, Chen YY, Liphardt J, Hwang ES, Weaver VM (2015) Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Intgr Biol 7(10):1120\u20131134. https:\/\/doi.org\/10.1039\/c5ib00040h","journal-title":"Intgr Biol"},{"issue":"6","key":"8077_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","volume":"110","author":"RO Hynes","year":"2002","unstructured":"Hynes RO, Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110(6):673\u2013687. https:\/\/doi.org\/10.1016\/S0092-8674(02)00971-6","journal-title":"Cell"},{"issue":"19","key":"8077_CR7","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1242\/jcs.03098","volume":"119","author":"JD Humphries","year":"2006","unstructured":"Humphries JD, Byron A, Humphries MJ (2006) Integrin ligands at a glance. J Cell Sci 119(19):3901. https:\/\/doi.org\/10.1242\/jcs.03098","journal-title":"J Cell Sci"},{"issue":"1","key":"8077_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9\u201322. https:\/\/doi.org\/10.1038\/nrc2748","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"8077_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier FJ, Jean C, Schlaepfer DD (2014) FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 14(9):598\u2013610. https:\/\/doi.org\/10.1038\/nrc3792","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"8077_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1023\/A:1022983000355","volume":"20","author":"B Felding-Habermann","year":"2003","unstructured":"Felding-Habermann B (2003) Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 20(3):203\u2013213. https:\/\/doi.org\/10.1023\/A:1022983000355","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"8077_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1158\/0008-5472.CAN-06-2768","volume":"67","author":"ES Yao","year":"2007","unstructured":"Yao ES, Zhang H, Chen Y-Y, Lee B, Chew K, Moore D, Park C (2007) Increased \u03b21 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 67(2):659\u2013664. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2768","journal-title":"Cancer Res"},{"issue":"1","key":"8077_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1083\/jcb.137.1.231","volume":"137","author":"VM Weaver","year":"1997","unstructured":"Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137(1):231\u2013245. https:\/\/doi.org\/10.1083\/jcb.137.1.231","journal-title":"J Cell Biol"},{"issue":"7","key":"8077_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.tips.2012.04.002","volume":"33","author":"SL Goodman","year":"2012","unstructured":"Goodman SL, Picard M (2012) Integrins as therapeutic targets. Trends Pharmacological Sci 33(7):405\u2013412. https:\/\/doi.org\/10.1016\/j.tips.2012.04.002","journal-title":"Trends Pharmacological Sci"},{"issue":"7","key":"8077_CR14","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/cancers11070978","volume":"11","author":"B Alday-Parejo","year":"2019","unstructured":"Alday-Parejo B, Stupp R, R\u00fcegg C (2019) Are integrins still practicable targets for anti-cancer therapy? Cancers 11(7):978. https:\/\/doi.org\/10.3390\/cancers11070978","journal-title":"Cancers"},{"key":"8077_CR15","doi-asserted-by":"crossref","unstructured":"Madamanchi A, Santoro SA, Zutter MM (2014) In: Gullberg D (ed I Domain Integrins. \u03b12\u03b21 Integrin. Springer, Netherlands, Dordrecht, pp 41\u201360","DOI":"10.1007\/978-94-017-9153-3_3"},{"key":"8077_CR16","doi-asserted-by":"publisher","unstructured":"Yeh Y-C, Lin H-H, Tang M-J (2012) A tale of two collagen receptors, integrin \u03b21 and discoidin domain receptor 1, in epithelial cell differentiation. Am J Physiol-Cell Physiol 303(12):C1207\u2013C1217. https:\/\/doi.org\/10.1152\/ajpcell.00253.2012","DOI":"10.1152\/ajpcell.00253.2012"},{"issue":"6","key":"8077_CR17","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/ncb1734","volume":"10","author":"I Taddei","year":"2008","unstructured":"Taddei I, Deugnier M-A, Faraldo MM, Petit V, Bouvard D, Medina D, F\u00e4ssler R, Thiery JP, Glukhova MA (2008) \u03b21 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol 10(6):716\u2013722. https:\/\/doi.org\/10.1038\/ncb1734","journal-title":"Nat Cell Biol"},{"key":"8077_CR18","doi-asserted-by":"publisher","unstructured":"Lampi MC, Reinhart-King CA (2018) Targeting extracellular matrix stiffness to attenuate disease: from molecular mechanisms to clinical trials. Sci Transl Med 10(422):eaao0475. https:\/\/doi.org\/10.1126\/scitranslmed.aao0475","DOI":"10.1126\/scitranslmed.aao0475"},{"issue":"17","key":"8077_CR19","doi-asserted-by":"publisher","first-page":"8648","DOI":"10.1158\/0008-5472.CAN-06-1544","volume":"66","author":"CL Hall","year":"2006","unstructured":"Hall CL, Dai J, van Golen KL, Keller ET, Long MW (2006) Type I collagen receptor (\u03b12\u03b21) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 66(17):8648\u20138654. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1544","journal-title":"Cancer Res"},{"issue":"1","key":"8077_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1172\/JCI42328","volume":"121","author":"NE Ramirez","year":"2011","unstructured":"Ramirez NE, Zhang Z, Madamanchi A, Boyd KL, O\u2019rear LD, Nashabi A, Li Z, Dupont WD, Zijlstra A, Zutter MM (2011) The \u03b1 2 \u03b2 1 integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 121(1):226\u2013237. https:\/\/doi.org\/10.1172\/JCI42328","journal-title":"J Clin Invest"},{"issue":"1","key":"8077_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10549-005-9089-4","volume":"97","author":"U Langsenlehner","year":"2006","unstructured":"Langsenlehner U, Renner W, Yazdani-Biuki B, Eder T, Wascher TC, Paulweber B, Clar H, Hofmann G, Samonigg H, Krippl P (2006) Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 97(1):67\u201372. https:\/\/doi.org\/10.1007\/s10549-005-9089-4","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"8077_CR22","doi-asserted-by":"publisher","first-page":"6906","DOI":"10.3390\/ijms22136906","volume":"22","author":"MNO Moritz","year":"2021","unstructured":"Moritz MNO, Merkel AR, Feldman EG, Selistre-de-Araujo HS, Rhoades (Sterling) JA (2021) Biphasic \u03b12\u03b21 integrin expression in breast cancer metastasis to bone. IJMS 22(13):6906. https:\/\/doi.org\/10.3390\/ijms22136906","journal-title":"IJMS"},{"issue":"3","key":"8077_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","volume":"122","author":"H Salmon","year":"2012","unstructured":"Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean M-C, Validire P, Trautmann A, Mami-Chouaib F, Donnadieu E (2012) Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 122(3):899\u2013910. https:\/\/doi.org\/10.1172\/JCI45817","journal-title":"J Clin Invest"},{"issue":"1","key":"8077_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-019-0556-6","volume":"7","author":"DE Kuczek","year":"2019","unstructured":"Kuczek DE, Larsen AMH, Thorseth M-L, Carretta M, Kalvisa A, Siersb\u00e6k MS, Sim\u00f5es AMC, Roslind A, Engelholm LH, Noessner E, Donia M, Svane IM, Straten PT, Gr\u00f8ntved L, Madsen DH (2019) Collagen density regulates the activity of tumor-infiltrating T cells. J Immunother Cancer 7(1):68. https:\/\/doi.org\/10.1186\/s40425-019-0556-6","journal-title":"J Immunother Cancer"},{"issue":"1","key":"8077_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","volume":"18","author":"Q Hu","year":"2025","unstructured":"Hu Q, Zhu Y, Mei J, Liu Y, Zhou G (2025) Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J Hematol Oncol 18(1):65. https:\/\/doi.org\/10.1186\/s13045-025-01717-y","journal-title":"J Hematol Oncol"},{"issue":"7693","key":"8077_CR26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel Iii EE, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, \u015eenbabao\u011flu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, H\u00f6glund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS et al (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544\u2013548. https:\/\/doi.org\/10.1038\/nature25501","journal-title":"Nature"},{"issue":"8","key":"8077_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00262-017-2003-1","volume":"66","author":"H Jiang","year":"2017","unstructured":"Jiang H, Hegde S, DeNardo DG (2017) Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. ImmunotherapyCancer Immunol Immunother 66(8):1037\u20131048. https:\/\/doi.org\/10.1007\/s00262-017-2003-1","journal-title":"ImmunotherapyCancer Immunol Immunother"},{"issue":"1","key":"8077_CR28","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1038\/s41598-021-81851-y","volume":"11","author":"VV Strelnikov","year":"2021","unstructured":"Strelnikov VV, Kuznetsova EB, Tanas AS, Rudenko VV, Kalinkin AI, Poddubskaya EV, Kekeeva TV, Chesnokova GG, Trotsenko ID, Larin SS, Kutsev SI, Zaletaev DV, Nemtsova MV, Simonova OA (2021) Abnormal promoter DNA hypermethylation of the integrin, nidogen, and dystroglycan genes in breast cancer. Sci Rep 11(1):2264. https:\/\/doi.org\/10.1038\/s41598-021-81851-y","journal-title":"Sci Rep"},{"issue":"3","key":"8077_CR29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4103\/1735-5362.371580","volume":"18","author":"S Jafarpour","year":"2023","unstructured":"Jafarpour S, Yazdi M, Nedaeinia R, Vatandoost N, Ferns GA, Salehi R (2023) Status of integrin subunit alpha 4 promoter DNA methylation in colorectal cancer and other malignant tumors: a systematic review and meta-analysis. Res Pharm Sci 18(3):231\u2013243. https:\/\/doi.org\/10.4103\/1735-5362.371580","journal-title":"Res Pharm Sci"},{"key":"8077_CR30","doi-asserted-by":"publisher","unstructured":"Busenhart P, Montalban-Arques A, Katkeviciute E, Morsy Y, Van Passen C, Hering L, Atrott K, Lang S, Garzon JFG, Naschberger E, Hartmann A, Rogler G, St\u00fcrzl M, Spalinger MR, Scharl M (2022) Inhibition of integrin \u03b1v\u03b26 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer. J Immunother Cancer 10(2):e003465. https:\/\/doi.org\/10.1136\/jitc-2021-003465","DOI":"10.1136\/jitc-2021-003465"},{"issue":"1","key":"8077_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ccell.2020.12.001","volume":"39","author":"A Bagati","year":"2021","unstructured":"Bagati A, Kumar S, Jiang P, Pyrdol J, Zou AE, Godicelj A, Mathewson ND, Cartwright ANR, Cejas P, Brown M, Giobbie-Hurder A, Dillon D, Agudo J, Mittendorf EA, Liu XS, Wucherpfennig KW (2021) Integrin \u03b1v\u03b26\u2013TGF\u03b2\u2013SOX4 pathway drives immune evasion in triple-negative breast cancer. Cancer Cell 39(1):54\u201367.e9. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.001","journal-title":"Cancer Cell"},{"issue":"4","key":"8077_CR32","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/cancers15041210","volume":"15","author":"H Ruan","year":"2023","unstructured":"Ruan H, Oike T, Sato H, Ando K, Ohno T (2023) Association between tumor mutational burden, stromal CD8+ tumor-infiltrating lymphocytes, and clinical factors in cervical cancers treated with radiotherapy. Cancers 15(4):1210. https:\/\/doi.org\/10.3390\/cancers15041210","journal-title":"Cancers"},{"key":"8077_CR33","doi-asserted-by":"publisher","first-page":"121378","DOI":"10.1016\/j.biomaterials.2022.121378","volume":"282","author":"C Robertson","year":"2022","unstructured":"Robertson C, Sebastian A, Hinckley A, Rios-Arce ND, Hynes WF, Edwards SA, He W, Hum NR, Wheeler EK, Loots GG, Coleman MA, Moya ML (2022) Extracellular matrix modulates T cell clearance of malignant cells in vitro. Biomaterials 282:121378. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121378","journal-title":"Biomaterials"},{"issue":"2\u20134","key":"8077_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1155\/2000\/56473","volume":"7","author":"P Friedl","year":"2000","unstructured":"Friedl P, Br\u00f6ker E-B (2000) T cell migration in three-dimensional ExtracellularMatrix: guidance by polarity and sensations. J Immunol Res 7(2\u20134):249\u2013266. https:\/\/doi.org\/10.1155\/2000\/56473","journal-title":"J Immunol Res"},{"key":"8077_CR35","doi-asserted-by":"publisher","unstructured":"Melssen MM, Sheybani ND, Leick KM, Slingluff CL Jr (2023) Barriers to immune cell infiltration in tumors. J Immunother Cancer 11(4):e006401. https:\/\/doi.org\/10.1136\/jitc-2022-006401","DOI":"10.1136\/jitc-2022-006401"},{"key":"8077_CR36","doi-asserted-by":"publisher","first-page":"1614228","DOI":"10.3389\/fimmu.2025.1614228","volume":"16","author":"T-T Chen","year":"2025","unstructured":"Chen T-T, Li X, Zhang Y, Kang X-J, Zhang S-F, Zhang T, Sangmao D, Zhu Y-J, Zhang D-K (2025) Breaking down physical barriers: strategies to improve lymphocyte infiltration for effective neoantigen-based therapies. Front Immunol 16:1614228. https:\/\/doi.org\/10.3389\/fimmu.2025.1614228","journal-title":"Front Immunol"},{"issue":"6","key":"8077_CR37","doi-asserted-by":"publisher","first-page":"2100285","DOI":"10.1002\/bies.202100285","volume":"44","author":"H Simsek","year":"2022","unstructured":"Simsek H, Klotzsch E (2022) The solid tumor microenvironment\u2014breaking the barrier for T cells. BioEssays 44(6):2100285. https:\/\/doi.org\/10.1002\/bies.202100285","journal-title":"BioEssays"},{"issue":"1","key":"8077_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/gutjnl-2022-327927","volume":"73","author":"M Canel","year":"2024","unstructured":"Canel M, S\u0142awi\u0144ska AD, Lonergan DW, Kallor AA, Upstill-Goddard R, Davidson C, von Kriegsheim A, Biankin AV, Byron A, Alfaro J, Serrels A (2024) FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer. Gut 73(1):131\u2013155. https:\/\/doi.org\/10.1136\/gutjnl-2022-327927","journal-title":"Gut"},{"issue":"7","key":"8077_CR39","doi-asserted-by":"publisher","first-page":"116500","DOI":"10.1016\/j.isci.2026.116500","volume":"29","author":"IR Eissa","year":"2026","unstructured":"Eissa IR, Cohen S, Boland GM, Sharova T, Tanabe KK (2026) The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. iScience 29(7):116500. https:\/\/doi.org\/10.1016\/j.isci.2026.116500","journal-title":"iScience"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08077-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08077-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08077-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:38:24Z","timestamp":1789533504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08077-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8077"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08077-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee (IACUC) and conducted in accordance with institutional and national ethical guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors reviewed and accepted the contents of the article.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"16"}}